Literature DB >> 18580624

Severe rhabdomyolysis associated with raltegravir use.

Teresa R Zembower, Lana Gerzenshtein, Karen Coleman, Frank J Palella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18580624     DOI： 10.1097/QAD.0b013e328303be40

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  14 in total

1.  Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Authors:  Jeffrey L Lennox; Edwin Dejesus; Daniel S Berger; Adriano Lazzarin; Richard B Pollard; Jose Valdez Ramalho Madruga; Jing Zhao; Hong Wan; Christopher L Gilbert; Hedy Teppler; Anthony J Rodgers; Richard J O Barnard; Michael D Miller; Mark J Dinubile; Bach-Yen Nguyen; Randi Leavitt; Peter Sklar
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

2.  Optimal use of raltegravir (Isentress(R)) in the treatment of HIV-infected adults - Canadian consensus guidelines.

Authors:  Anita Rachlis; Jonathan B Angel; Marianne Harris; Stephen D Shafran; Rachel Therrien; Cécile Tremblay; Mark A Wainberg
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

Review 3.  Prescribing for patients taking antiretroviral therapy.

Authors:  Yasmin Hughes; Louise Tomlins; Tim Usherwood
Journal:  Aust Prescr       Date:  2022-06-01

4.  Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

Authors:  Kavya Ramkumar; Nouri Neamati
Journal:  Core Evid       Date:  2010-06-15

5.  Nephrotoxicity of HAART.

Authors:  Robert Kalyesubula; Mark A Perazella
Journal:  AIDS Res Treat       Date:  2011-08-15

6.  Role of raltegravir in the management of HIV-1 infection.

Authors:  N Lance Okeke; Charles Hicks
Journal:  HIV AIDS (Auckl)       Date:  2011-07-15

7.  Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis.

Authors:  Sylvain Raoul Simeni Njonnou; Sophie Henrard; Lamya Noure; Jean-Christophe Goffard
Journal:  BMJ Case Rep       Date:  2020-07-01

Review 8.  HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.

Authors:  Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

Review 9.  Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.

Authors:  Edwin Coleridge S Naidu; Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Carmen Olivia Rennie; Onyemaechi Okpara Azu
Journal:  Pharmacol Res Perspect       Date:  2021-05

10.  The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation.

Authors:  Olivier Delelis; Isabelle Malet; Li Na; Luba Tchertanov; Vincent Calvez; Anne-Genevieve Marcelin; Frederic Subra; Eric Deprez; Jean-François Mouscadet
Journal:  Nucleic Acids Res       Date:  2009-01-07       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.